Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Like
Tweet
Print
Chad Orevillo, MPH
Executive Vice President and Head of Operations
Longboard Pharmaceuticals
Poster(s):
060: A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma & CSF Pharmacokinetics & QEEG Changes Reflecting Receptor Engagement
Sunday, September 10, 2023
5:00 PM - 7:00 PM
PT